$CVM Now that our guest panelists have had their shots Editor Bob Flaherty finally gets to the plate. Batter up!
Early on in this issue I promised to set an example and not recommend my last year's pick of CEL-SCI Corporation (NYSE:CVM-$0.09) down 83%. That is not because I don't still believe a turnaround is possible but I can't ask everyone else to think of the team and not do so myself.
As explained our homepage http://www.flahertyfinancialnews.com column three CEL-SCI may yet become a modern little David and take down a modern day rollup Goliath.
The FDA could lift its partial global hold on CEL-SCI's global cancer immunotherapy head and neck cancer study.
Also CEL-SCI could win its seemingly endless $150 million arbitration suit against its initial discharged Clinical Research Organization now part of
that powerful rollup or at least win a very large settlement.
But the future is unknowable and it may not either.
Still it could win.
It is the only company to be administering Phase III pioneering immunotherapy treatment first before the healthy immune systems of
newly diagnosed cancer patients has been debilitated.
That's because CEL-SCI's three-week Multikine immunotherapy
treatment is the only one which can fit into the four- week window
before the current damaging standard of care-
surgery, radiation and chemotherapy-
devastates the patients' immune systems.
If successful, administering immunotherapy first makes common sense.
A healthy immune system should be able to kill more cancer cells than an anemic debilitated one.
Early on in this issue I promised to set an example and not recommend my last year's pick of CEL-SCI Corporation (NYSE:CVM-$0.09) down 83%. That is not because I don't still believe a turnaround is possible but I can't ask everyone else to think of the team and not do so myself.
As explained our homepage http://www.flahertyfinancialnews.com column three CEL-SCI may yet become a modern little David and take down a modern day rollup Goliath.
The FDA could lift its partial global hold on CEL-SCI's global cancer immunotherapy head and neck cancer study.
Also CEL-SCI could win its seemingly endless $150 million arbitration suit against its initial discharged Clinical Research Organization now part of
that powerful rollup or at least win a very large settlement.
But the future is unknowable and it may not either.
Still it could win.
It is the only company to be administering Phase III pioneering immunotherapy treatment first before the healthy immune systems of
newly diagnosed cancer patients has been debilitated.
That's because CEL-SCI's three-week Multikine immunotherapy
treatment is the only one which can fit into the four- week window
before the current damaging standard of care-
surgery, radiation and chemotherapy-
devastates the patients' immune systems.
If successful, administering immunotherapy first makes common sense.
A healthy immune system should be able to kill more cancer cells than an anemic debilitated one.
